EUVIMEDEUVIMED entdecken
Open Access

Risk Stratification in Older Intensively Treated Patients With AML

Jurjen Versluis iD, Marlen Metzner iD, Ariel Wang iD, Patrycja Gradowska, Abin Thomas iD, Niels Asger Jakobsen iD, Alison Kennedy iD, Rachel Moore, Emma Boertjes iD, Christian M Vonk iD, Francois G Kavelaars, Melissa Rijken und 22 weitere

Journal of Clinical Oncology · 2024-12 · 42 (34) · 4084-4094

DOI: 10.1200/jco.23.02631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024-12. Verfasst von Jurjen Versluis und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HCT). Thus, there is an urgent need in clinical practice for a prognostic model to identify older patients with AML who benefit from curative treatment. METHODS We studied 1,910 intensively treated patients older than 60 years with AML and high-risk myelodysplastic syndrome (HR-MDS) from two cohorts (NCRI-AML18 and HOVON-SAKK). The median patient age was 67 years. Using a random survival forest, clinical, molecular, and cytogenetic variables were evaluated in an AML development cohort (n = 1,204) for association with overall survival (OS). Relative weights of selected variables determined the prognostic model, which was validated in AML (n = 491) and HR-MDS cohorts (n = 215). RESULTS The complete cohort had a high frequency of poor-risk features, including 2022 European LeukemiaNet adverse-risk (57.3%), mutated TP53 (14.4%), and myelodysplasia-related genetic features (65.1%). Nine variables were used to construct four groups with highly distinct 4-year OS in the (1) AML development, (2) AML validation, and (3) HR-MDS test cohorts ([1] favorable: 54% ± 4%, intermediate: 38% ± 2%, poor: 21% ± 2%, very poor: 4% ± 1%; [2] 54% ± 9%, 43% ± 4%, 27% ± 4%, 4% ± 3%; and [3] 54% ± 10%, 33% ± 6%, 14% ± 5%, 0% ± 3%, respectively). This new AML60+ classification improves current prognostic classifications. Importantly, patients within the AML60+ intermediate- and very poor-risk group significantly benefited from allo-HCT, whereas the poor-risk patients showed an indication, albeit nonsignificant, for improved outcome after allo-HCT. CONCLUSION The new AML60+ classification provides prognostic information for intensively treated patients 60 years and older with AML and HR-MDS and identifies patients who benefit from intensive chemotherapy and allo-HCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesHumansAgedMaleFemaleMiddle AgedRisk AssessmentPrognosisAged, 80 and overCohort StudiesAge FactorsRisk Factors

Autor:innen und Institutionen

  • Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
  • HOVON Foundation, Rotterdam, the Netherlands.
  • Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom.
  • School of Medicine, Cardiff University, Cardiff, United Kingdom.

ORCID-Profile: Jurjen Versluis, Marlen Metzner, Ariel Wang, Abin Thomas, Niels Asger Jakobsen, Alison Kennedy, Emma Boertjes, Christian M Vonk, Amanda Gilkes, H Berna Beverloo, Markus Manz, Catharina H M J Van Elssen, Lidwine W Tick, Sylvie D Freeman, Jonathan A Cook, Steven Knapper, Charles Craddock, Bob Löwenberg, Nigel Russell, Peter J M Valk, Paresh Vyas

Zitieren

APA

Versluis, J., Metzner, M., Wang, A., Gradowska, P., Thomas, A., Jakobsen, N. A., Kennedy, A., Moore, R., Boertjes, E., Vonk, C. M., Kavelaars, F. G., Rijken, M., Gilkes, A., Schwab, C., Beverloo, H. B., Manz, M., Visser, O., Van Elssen, C. H. M. J., de Weerdt, O., …, & Vyas, P. (2024). Risk Stratification in Older Intensively Treated Patients With AML. Journal of Clinical Oncology, 42(34), 4084-4094. https://doi.org/10.1200/jco.23.02631

Vancouver

Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, et al. Risk Stratification in Older Intensively Treated Patients With AML. Journal of Clinical Oncology. 2024;42(34):4084-4094. doi:10.1200/jco.23.02631

BibTeX
@article{Versluis2024,
  author = {Versluis, Jurjen and Metzner, Marlen and Wang, Ariel and Gradowska, Patrycja and Thomas, Abin and Jakobsen, Niels Asger and Kennedy, Alison and Moore, Rachel and Boertjes, Emma and Vonk, Christian M and Kavelaars, Francois G and Rijken, Melissa and Gilkes, Amanda and Schwab, Claire and Beverloo, H Berna and Manz, Markus and Visser, Otto and Van Elssen, Catharina H M J and de Weerdt, Okke and Tick, Lidwine W and Biemond, Bart J and Vekemans, Marie-Christiane and Freeman, Sylvie D and Harrison, Christine J and Cook, Jonathan A and Dennis, Mike and Knapper, Steven and Thomas, Ian and Craddock, Charles and Ossenkoppele, Gert J and Löwenberg, Bob and Russell, Nigel and Valk, Peter J M and Vyas, Paresh},
  title = {Risk Stratification in Older Intensively Treated Patients With AML},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {34},
  pages = {4084--4094},
  doi = {10.1200/jco.23.02631}
}
Kostenlos starten →